Real-world experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience
Background: CD19-directed chimeric antigen T-cell receptor (CAR-T) therapies have revolutionized the treatment of patients with relapsed/refractory (R/R) aggressive B-cell lymphomas (aBCL). The results of the landmark ZUMA-1 and JULIET trials have been reproducible in real-world settings across multiple institutions, and patients with double (DHL) or triple (THL) hit lymphomas have demonstrated non-inferior outcomes compared to non-DHL/THL counterparts.Methods: This retrospective cohort study included 53 patients with R/R aBCL who received CAR-T from 10/2017-6/2020 at the University of California, Los Angeles (UCLA).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Sanaz Ghafouri, Kathleen Fenerty, Gary Schiller, Sven de Vos, Herbert Eradat, John Timmerman, Sarah Larson, Monica Mead Source Type: research